Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (4966)	1/11/2016 7:26:02 PM
From: mopgcw	Read Replies (1) of 4974

So Mark gets on the board to help? not sure i recall hime being on one before. Oncothyreon has appointed two new members to its Board of Directors, Mark Lampert and Gwen Fyfe, M.D. Mr. Lampert is the founder of BVF Partners L.P., affiliates of which, including the Biotechnology Value Fund, L.P., have been shareholders of Oncothyreon since 2011."We remain on track to initiate a potentially pivotal Phase 2 clinical trial of ONT-380 in combination with Xeloda (capecitabine) and Herceptin (trastuzumab) early this year. Our development and regulatory teams are focused on bringing this important medicine to the market for advanced-stage breast cancer patients as soon as .....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next